Evidence map›Paper›PMID 41450930›Full record

ArticleFrontiers in oncology2025

Outcomes with frontline immune checkpoint inhibitors among individuals with

Julian A Marin-Acevedo, Ram Thapa, Sudeepthi V Bandikatla, Dung-Tsa Chen, J Kevin Hicks, Jhanelle E Gray, Sonam Puri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julian A Marin-AcevedoThoracic Oncology, Division of Hematology and Medical Oncology, Department of Internal Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
Ram ThapaDepartment of Biostatistics, Moffitt Cancer Center, Tampa, FL, United States.
Sudeepthi V BandikatlaDivision of Hematology and Medical Oncology, University of South Florida, Tampa, FL, United States.
Dung-Tsa ChenDepartment of Biostatistics, Moffitt Cancer Center, Tampa, FL, United States.
J Kevin HicksDivision of Individualized Cancer Management, Moffitt Cancer Center, Tampa, FL, United States.
Jhanelle E GrayDepartment of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Sonam PuriDepartment of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oncogenic Methods: We retrospectively analyzed patients with Results: Among 122 individuals, 54 had Class I and 68 had non-Class I mutations. For Class I mutations, ICIs yielded a PFS of 9.2 months and OS of 42.2 months, representing a significant OS advantage over chemotherapy-alone (22.2 months; Conclusion: ICIs appear effective in

Indexed as

adenocarcinomaBRAF mutationsdriver mutationsimmunotherapyNSCLCPD-L1smokingtargeted therapy

Identifiers

PMID41450930
PMCPMC12727587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.